Concepedia

Megan Crumbaker

MC

30

Publications

1.4K

Citations

19

H-Index

2018

Active since

Affiliations

The Kinghorn Cancer Centre(Current)

St Vincent's Hospital Sydney

The University of Sydney

Garvan Institute of Medical Research

Peter MacCallum Cancer Centre

Megan Crumbaker is an author at The Kinghorn Cancer Centre specializing in medicine, urology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2018–2025

30

Publications

30

Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial <sup>68</sup>Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade

Louise Emmett, Charlotte Yin, Megan Crumbaker et al. · Journal of Nuclear Medicine · 2018 · 199 citations · Full text

Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression

Louise Emmett, Megan Crumbaker, Bao Ho et al. · Clinical Genitourinary Cancer · 2018 · 177 citations

, , +7

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet Oncology · 2023 · 172 citations

, , +8

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Louise Emmett, Shalini Subramaniam, Megan Crumbaker et al. · The Lancet Oncology · 2024 · 123 citations

, , +7

LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).

Shahneen Sandhu, Anthony M. Joshua, Louise Emmett et al. · Journal of Clinical Oncology · 2023 · 63 citations

, , +18

Rows per page

1–5 of 30